Sleep disturbance in supportive care of cancer: A review

Journal of Palliative Medicine

Volumn 9, Issue 2, 2006, Pages 437-450

  Kvale, Elizabeth A ^a   Shuster, John L ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; DOXEPIN; ESZOPICLONE; HALOPERIDOL; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; MELATONIN; MIRTAZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ADVANCED CANCER; BEHAVIOR THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CAREGIVER; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; HUMAN; INSOMNIA; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER;

HUMANS; NEOPLASMS; PALLIATIVE CARE; SLEEP INITIATION AND MAINTENANCE DISORDERS; UNITED STATES;

EID: 33646560638     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.9.437     Document Type: Review

References (135)

1. Kryger M, Roth T, Dement W (eds): Principles and Practice of Sleep Medicine, 3rd ed. Philadelphia: W.B. Saunders Company, 2000.
2. Morgan K: Daytime activity and risk factors for late-life insomnia. J Sleep Res 2003;12:231-238.
3. Sheely L: Sleep disturbances in hospitalized patients with cancer. Oncol Nurs Forum 1996;23:109-111.
4. Brescia F, Adler D, Gray G, Ryan M, Cimino J, Mamtami R: Hospitalized advanced cancer patients: A profile. J Pain Symptom Manage 1990;5:221-227.
5. Ahles T, Ruckdeschel J, Blanchard E: Cancer-related pain-1. Prevalence in an outpatient setting as a function of stage of disease and type of cancer. J Psychosomat Res 1984;28:115-119.
6. Daut R, Cleeland C: The prevalence and severity of pain in cancer. Cancer 1982;50:1913-1918.
7. Dorrepaal K, Aaronson N, van Dam F: Pain experience and pain management among hospitalized cancer patients. Cancer 1989;63:593-598.
8. Ahmedzai S: Palliation of respiratory symptoms. In: Doyle E, Hanks G, MacDonald N (eds): Oxford Textbook of Palliative Medicine, 2nd ed. New York: Oxford University Press; 1998, pp. 583-616.
9. Shuster JL Jr, Breitbart W, Chochinov HM: Psychiatric aspects of excellent end-of-life care. Ad Hoc Committee on End-of-Life Care. The Academy of Psychosomatic Medicine. Psychosomatics 1999;40:1-4.
10. Stark D, Kiely A, Smith A, Velikova G, House A, Selby P: Anxiety disorders in cancer patients: Their nature, associations, and relation to quality of life. J Clin Oncol 2002;20:3137-3148.
11. Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, Vela-Bueno A, Kales A, Chrousos GP: Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002;51:887-892.
12. Vgontzas AN, Papanicolaou DA, Bixler EO, et al: Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603-2607.
13. Krueger JM, Majde JA, Obal F: Sleep in host defense. Brain Behav Immun 2003;17(Suppl 1):S41-47.
14. Cleeland S, Bennett G, Dantzer R, et al: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? Cancer 2003;97:2919-2925.
15. Reichenberg A YR, Schuld A, Draus T, Haack M, Morag A, Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
16. Bower JE GP, Aziz N, Fahey JL: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomat Med 2002;64:604-611.
17. Maier SF, Watkins LR: Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain, Behav Immun 2003;17(Suppl 1):S125-131.
18. Geinitz H, Zimmerman FB, Stoll P, Thamm R, Kaffenberger W, Ansorg K, Keller M, Busch R, van Bueningen D, Molls M: Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001;51:691-698.
19. Pollmacher T, Schuld A, Kraus T, Haack M, Hinzeselch D, Mullington J: Experimental Immunomodulation, Sleep, and Sleepiness in Humans. Ann NY Acad Sci 2000;917:478-487.
20. Moldofsky H, Dickstein J: Sleep and cytokine-immune functions in medical, psychiatric and primary sleep disorders. Sleep Med Rev 1999;3:325-337.
21. Prolo P, Chiappelli F, Fiorucci A, Dovio A, Sartori M, Angeli A: Psychoneuroimmunology: New avenues of research for the twenty-first century. Ann NY Acad Sci 2002;966:400-408.
22. Koopman C, Nouriani B, Erickson V, Anupindi R, Butler LD, Bachman MH, Sephton SE, Spiegel D: Sleep disturbances in women with metastatic breast cancer. Breast J 2002;8:362-370.
23. Degner LF, Sloan JA: Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 1995;10:423-431.
24. Davidson JR, Waisberg JL, Brundage MD, MacLean AW: Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology 2001;10:389-397.
25. Ginsburg ML, Quirt C, Ginsburg AD, MacKillop WJ: Psychiatric illness and psychosocial concerns of patients with newly diagnosed lung cancer. [see comment]. CMAJ 1995;152:701-708.
26. Harrison LB, Zelefsky MJ, Pfister DG, Carper E, Raben A, Kraus DH, Strong EW, Rao A, Thaler H, Polyak T, Portenoy R: Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 1997;19:169-175.
27. Kurtz ME, Kurtz JC, Given CW, Given B: Loss of physical functioning among patients with cancer: a longitudinal view. Cancer Pract 1993;1:275-281.
28. Lindley C, Vasa S, Sawyer WT, Winer EP: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998;16:1380-1387.
29. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, Smart-Curley T, Komeny N, Norton L, Hoskins W: Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994;3:183-189.
30. Sarna L: Correlates of symptom distress in women with lung cancer. Cancer Pract 1993;1:21-28.
31. Savard J, Simard S, Blanchet J, Ivers H, Morin CM: Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001;24:583-590.
32. Engstrom CA, Strohl RA, Rose L, Lewandowski L, Stefanek ME: Sleep alterations in cancer patients. Cancer Nurs 1999;22:143-148.
33. Couzi RJ, Helzlsouer KJ, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-2744.
34. Kaye J, Kaye K, Madow L: Sleep patterns in patients with cancer and patients with cardiac disease. J Psychol 1983;114(1st Half):107-113.
35. Krech RL, Walsh D: Symptoms of pancreatic cancer. J Pain Symptom Manage 1991;6:360-367.
36. Lindley C, Vasa S, Sawyer WT, Winer EP: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998;16:1380-1387.
37. Malone M, Harris AL, Luscombe DK: Assessment of the impact of cancer on work, recreation, home management and sleep using a general health status measure. J R Soc Med 1994;87:386-389.
38. Savard J, Morin CM: Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol 2001:895-908.
39. The International Classification of Sleep Disorders. Rochester, MN: American Sleep Disorders Association, 1997.
40. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4 ed. Washington, D.C.: American Psychiatric Association, 1994.
41. Ford D, Kamerow D: Epidemiologic study of sleep disturbances and psychiatric disorders: An opportunity for prevention? JAMA 1989;262:1479-1484.
42. Davidson JR, MacLean AW, Brundage MD, Schulze K: Sleep disturbance in cancer patients. Soc Sci Med 2002;54:1309-1321.
43. Berger AM, Higginbotham P: Correlates of fatigue during and following breast cancer chemotherapy: A pilot study. Oncol Nurs Forum 2000;27:1443-1448.
44. Hugel H, Ellershaw J, Cook L, Skinner J, Irvine C: The prevalence, key causes, and management of insomnia in palliative care patients. J Pain Symptom Manage 2004;27:316-321.
45. Mercadante S, Girelli D, Casuccio A: Sleep disorders in advanced cancer patients: Prevalence and factors associated. Support Care Cancer 2004;12:355-359.
46. Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P: Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol 1993;11:997-1004.
47. Fortner B, Stepanski E, Wang S, Kasprowicz S, Durrence H: Sleep and quality of life in breast cancer patients. J Pain Symptom Manage 2002;24:471-480.
48. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA: Quality of life in people with insomnia. Sleep 1999;22(Suppl 2):S379-385.
49. Redeker NS, Lev EL, Ruggiero J: Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000;14:275-290; discussion 91-98.
50. Katz DA, McHorney CA: The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002;51:229-235.
51. Kurtz ME, Kurtz JC, Given CW, Given B: Relationship of caregiver reactions and depression to cancer patients' symptoms, functional states and depression-A longitudinal view. Soc Sci Med 1995;40:837-846.
52. Savard MH, Savard J, Simard S, Ivers H: Empirical validation of the Insomnia Severity Index in cancer patients. Psychooncology 2005;14:429-441.
53. Ohayon MM, Caulet M, Priest RG, Guilleminault C: Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 1998;51:273-283.
54. Ohayon MM, Lader MH: Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002;63:817-825.
55. Pagel JF, Parnes BL: Medications for the treatment of sleep disorders: An overview. Primary Care Companion J Clin Psychiatry 2001;3:118-125.
56. The American Psychiatric Association Taskforce on Benzodiazepine Dependency: Benzodiazepine Dependence, Toxicity, and Abuse. Washington, D.C.: American Psychiatric Association, 1990.
57. Poyares D, Guilleminault C, Ohayon MM, Tufik S: Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 2004;38:327-334.
58. Kupfer D, Reynolds C: Current concepts: Management of insomnia. N Engl J Med 1997;336:341-346.
59. Drover DR: Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: Zaleplon, zolpidem, and zopiclone. Clin Pharmacokinet 2004;43:227-238.
60. Voshaar RC, van Balkom AJ, Zitman FG: Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol 2004;14:301-306.
61. Bain K, Weschules D, Knowlton C, Gallagher R: Toward evidence-based prescribing at end of life: A comparative review of temazepam and zolpidem for the treatment of insomnia. Am J Hosp Palliat Care 2003;20:382-388.
62. Krystal A, Walsh J, Laska E, et al: Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-797.
63. Hirst A, Sloan R: Benzodiazepines and related drugs for insomnia in palliative care (Cochrane review). In: The Cochrane Library. Oxford: Update Software; 2003.
64. Sateia MJ, Pigeon WR: Identification and management of insomnia. Med Clin North Am 2004;88:567-96, vii.
65. Ferrari A, Coccia CP, Bertolini A, Sternieri E: Methadone-Metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-559.
66. Corkery JM, Schifano F, Ghodse AH, Oyefeso A: The effects of methadone and its role in fatalities. Hum Psychopharmacol 2004;19:565-576.
67. Hajak G, Rodenbeck A, Voderholzer U, et al: Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomngraphic study. J Clin Psychiatry 2001;62:453-463.
68. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS: Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002;22:137-147.
69. Nowell PD, Reynolds CF, 3rd, Buysse DJ, Dew MA, Kupfer DJ: Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999;60:89-95.
70. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-100.
71. Ohayon MM, Caulet M, Arbus L, et al: Are prescribed medications effective in the treatment of insomnia complaints? J Psychosomat Res 1999;47:359-368.
72. Parrino L, Spaggiari M, Boselli M, Giovanni G, Terzano M: Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology 1994;116:389-395.
73. Mashiko H, Shin-ichi N, Kumashiro H, Kaneko Y, Suzuki S, Numata Y, Horikoshi R, Watanabe Y: Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: Dose-finding study with no concomitant use of hypnotic agent. Psychiatry Clin Neurosci 1999;53:193-194.
74. Saletu-Zyhlarz G, Abu-Bakr M, Anderer P, et al: Insomnia in depression: Differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249-260.
75. Kast RE: Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001;9:469-470.
76. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD: An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002;23:442-447.
77. Davis MP, Dickerson ED, Pappagallo M, Benedetti C, Grauer PA, Lycan J: Mirtazepine: heir apparent to amitriptyline? Am J Hosp Palliat Care 2001;18:42-46.
78. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S: Mirtazapine for pruritus. J Pain Symptom Manage 2003;25:288-291.
79. Davis MP, Khawam E, Pozuelo L, Lagman R: Management of symptoms associated with advanced cancer: Olanzapine and mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther 2002;2:365-376.
80. Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S: The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 1999;14:851-857.
81. Basu R, Dodge H, Stoehr GP, Ganguli M: Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: Effects on cognition. Am J Geriatr Psychiatry 2003;11:205-213.
82. Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE: Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 2003;23:260-268.
83. Jan J, Espezel H, Appleton R: The treatment of sleep disorders with melatonin. Dev Med Child Neurol 1994;36:97-107.
84. Haimov I, Lavie L: Melatonin replacement of elderly insomniacs. Sleep 1995;18:598-603.
85. Cajochen C, Krauchi K, Wirz-Justice A: The role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003;15:432-437.
86. Lissoni P, Meregalli S, Nosseto L: Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996;53:43-46.
87. Balderer G, Borbely AA: Effect of valerian on human sleep. Psychopharmacology (Berl) 1985;87:406-409.
88. Leathwood PD, Chauffard F, Heck E, Munoz-Box R: Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982;17:65-71.
89. Lindahl O, Lindwall L: Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989;32:1065-1066.
90. Poyares DR, Guilleminault C, Ohayon MM, Tufik S: Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry 2002;26:539-545.
91. Hadley S, Petry JJ: Valerian. Am Fam Physician 2003;67:1755-1758.
92. Sparreboom A, Cox MC, Acharya MR, Figg WD: Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.
93. Geier FP, Konstantinowicz T: Kava treatment in patients with anxiety. Phytother Res 2004;18:297-300.
94. Thomsen M, Vitetta L, Schmidt M, Sali A: Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2004;180:198-199; author reply 199.
95. Anke J, Ramzan I: Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst, f.). J Ethnopharmacol 2004;93:153-160.
96. Block K, Gyllenhaal C, Mead M: Safety and efficacy of herbal sedatives in cancer care, Integrative Cancer Therapies 2004;3:128-148.
97. Breitbart W, Tremblay A, Gibson C: An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002;43:175-182.
98. Kim KY, Bader GM, Kotlyar V, Cropper D: Treatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol 2003;16:29-31.
99. Pae CU, Lee SJ, Lee CU, Lee C, Paik IH: A pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol 2004;19:125-127.
100. Schwartz TL, Masand PS: Treatment of delirium with quetiapine. Prim Care Companion J Clin Psychiatry 2000;2:10-12.
101. Akechi T, Uchitomi Y, Okamura H, Fukue M, Kagaya A, Nishida A, Oomori N, Yamawaki S: Usage of haloperidol for delirium in cancer patients. Support Care Cancer 1996;4:390-392.
102. Breitbart W, Marotta R, Platt MM, et al: A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-237.
103. Han CS, Kim YK: A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45:297-301.
104. Morita T, Tsunoda J, Inoue S, Chihara S, Oka K: Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients: A validation study. Palliat Med 2001;15:197-206.
105. Massie MJ, Holland J, Glass E: Delirium in terminally ill cancer patients. Am J Psychiatry 1983;140:1048-1050.
106. Breitbart W, Strout D: Delirium in the terminally ill. Clin Geriatr Med 2000;16:357-372.
107. Morin CM, Culbert J, Schwartz S: Non-pharmacological interventions for insomnia. Am J Psychiat 1994;151:1172-1180.
108. Morin C, Colecchi C, Stone J, Sood R, Brink D: Behavioral and pharmacological therapies for late-life insomnia. JAMA 1999;281:391-999.
109. Murtagh D, Greenwood K: Identifying effective psychological treatments for insomnia: A meta-analysis. J Consult Clin Psychol 1995;63:79-89.
110. Chesson A, Anderson W, Littner M: Practice parameters for the non-pharmacologic treatment of chronic insomnia. Sleep 1999;22:1128-1133.
111. Edinger J, WK W, Radtke R, Marsh G, Quillian R: Cognitive behavioral therapy for treatment of chronic primary insomnia. JAMA 2001;285:1856-1864.
112. Harvey L, Inglis SJ, Espie CA: Insomniacs' reported use of CBT components and relationship to long-term clinical outcome. Behav Res Ther 2002;40:75-83.
113. Stepanski E, Wyatt J: Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7:215-225.
114. Friedman L, Benson K, Noda A, et al: An actigraphic comparison of sleep restriction and sleep hygiene treatments for insomnia in older adults. J Geriatr Psychiatry Neurol 2000;13:17-27.
115. Bonnet MH, Arand DL: Hyperarousal and insomnia. Sleep Med Rev 1997;1:97-108.
116. Means MK, Lichstein KL, Epperson MT, Johnson CT: Relaxation therapy for insomnia: Nighttime and day time effects. Behav Res Ther 2000;38:665-678.
117. Lichstein KL, Riedel BW, Wilson NM, Lester KW, Aguillard RN: Relaxation and sleep compression for late-life insomnia: A placebo-controlled trial. J Consult Clin Psychol 2001;69:227-239.
118. Jacobs GD, Rosenberg PA, Friedman R, Matheson J, Peavy GM, Domar AD, Benson H: Multifactor behavioral treatment of chronic sleep-onset insomnia using stimulus control and the relaxation response. A preliminary study. Behav Modif 1993;17:498-509.
119. Freedman R, Papsdorf JD: Biofeedback and progressive relaxation treatment of sleep-onset insomnia: A controlled, all-night investigation. Biofeedback Self Regul 1976;1:253-271.
120. Borkovec TD, Grayson JB, O'Brien GT, Weerts TC: Relaxation treatment of pseudoinsomnia and idiopathic insomnia: An electroencephalographic evaluation. J Appl Behav Anal 1979;12:37-54.
121. Nicassio PM, Boylan MB, McCabe TG: Progressive relaxation, EMG biofeedback and biofeedback placebo in the treatment of sleep-onset insomnia. Br J Med Psychol 1982;55(Pt 2):159-166.
122. Lichstein KL, Johnson RS: Relaxation for insomnia and hypnotic medication use in older women. Psychol Aging 1993;8:103-111.
123. Harvey AG, Payne S: The management of unwanted pre-sleep thoughts in insomnia: Distraction with imagery versus general distraction. Behav Res Ther 2002;40:267-277.
124. Morin CM, Azrin NH: Stimulus control and imagery training in treating sleep-maintenance insomnia. J Consult Clin Psychol 1987;55:260-262.
125. Spielman AJ, Saskin P, Thorpy MJ: Treatment of chronic insomnia by restriction of time in bed. Sleep 1987;10:45-56.
126. Hoelscher TJ, Edinger JD: Treatment of sleep-maintenance insomnia in older adults: Sleep period reduction, sleep education, and modified stimulus control. Psychol Aging 1988;3:258-263.
127. Riedel BW, Lichstein KL, Dwyer WO: Sleep compression and sleep education for older insomniacs: Self-help versus therapist guidance. Psychol Aging 1995;10:54-63.
128. Lacks P, Bertelson AD, Sugerman J, Kunkel J: The treatment of sleep-maintenance insomnia with stimulus-control techniques. Behav Res Ther 1983;21:291-295.
129. Baillargeon L, Demers M, Ladouceur R: Stimulus-control: Nonpharmacologic treatment for insomnia. Can Fam Physician 1998;44:73-79.
130. Childs-Clarke A: Stimulus control techniques for sleep onset insomnia. Nurs Times 1990;86:52-53.
131. Simeit R, Deck R, Conta-Marx B: Sleep management training for cancer patients with insomnia. Support Care Cancer 2004;12:176-183.
132. Cannici J, Malcolm R, Peek LA: Treatment of insomnia in cancer patients using muscle relaxation training. J Behav Ther Exp Psychiatry 1983;14:251-256.
133. Stam HJ, Bultz BD: The treatment of severe insomnia in a cancer patient. J Behav Ther Exp Psychiatry 1986;17:33-37.
134. Bruera E, Fainsinger R, Schoeller T, Ripamonti C: Rapid discontinuation of hypnotics in terminal cancer patients: A prospective study. Ann Oncol 1996;7:855-856.
135. Edinger J, Sampson W: A primary care "friendly" cognitive behavioral insomnia therapy. Sleep 2003;26:177-182.